Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting